Esophageal and Esophagogastric Junction Cancers, Version 1.2015

JemalABrayFCenterMM. Global cancer statistics. CA Cancer J Clin2011;61:69–90.

JemalABrayFCenterMM. Global cancer statistics. CA Cancer J Clin2011;61:69–90. )| false
• Search Google Scholar
• Export Citation

SiegelRMaJZouZJemalA. Cancer statistics, 2014. CA Cancer J Clin2014;64:9–29.

SiegelRMaJZouZJemalA. Cancer statistics, 2014. CA Cancer J Clin2014;64:9–29. )| false
• Search Google Scholar
• Export Citation

CorleyDABufflerPA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol2001;30:1415–1425.

CorleyDABufflerPA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol2001;30:1415–1425. )| false
• Search Google Scholar
• Export Citation

PickensAOrringerMB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg2003;76:S1367–1369.

PickensAOrringerMB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg2003;76:S1367–1369. )| false
• Search Google Scholar
• Export Citation

SiewertJRKatjaO. Are squamous and adenocarcinomas of the esophagus the same disease?Semin Radiat Oncol2007;17:38–44.

SiewertJRKatjaO. Are squamous and adenocarcinomas of the esophagus the same disease?Semin Radiat Oncol2007;17:38–44. )| false
• Search Google Scholar
• Export Citation

BrownLMDevesaSSChowWH. Incidence of adenocarcinoma of the esophagus among white americans by sex, stage, and age. J Natl Cancer Inst2008;100:1184–1187.

BrownLMDevesaSSChowWH. Incidence of adenocarcinoma of the esophagus among white americans by sex, stage, and age. J Natl Cancer Inst2008;100:1184–1187. )| false
• Search Google Scholar
• Export Citation

SiewertJRSteinHJFeithM. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg2001;234:360–367.

SiewertJRSteinHJFeithM. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg2001;234:360–367. )| false
• Search Google Scholar
• Export Citation

EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual.7th edition. New York, NY: Springer; 2010.

EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual.7th edition. New York, NY: Springer; 2010. )| false
• Search Google Scholar
• Export Citation

RiceTWRuschVWApperson-HansenC. Worldwide esophageal cancer collaboration. Dis Esophagus2009;22:1–8.

RiceTWRuschVWApperson-HansenC. Worldwide esophageal cancer collaboration. Dis Esophagus2009;22:1–8. )| false
• Search Google Scholar
• Export Citation

KimTJKimHYLeeKWKimMS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics2009;29:403–421.

KimTJKimHYLeeKWKimMS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics2009;29:403–421. )| false
• Search Google Scholar
• Export Citation

SiewertJR. Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection. Dis Esophagus1996;9:173–182.

SiewertJR. Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection. Dis Esophagus1996;9:173–182. )| false
• Search Google Scholar
• Export Citation

SiewertJRFeithMWernerMSteinHJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg2000;232:353–361.

SiewertJRFeithMWernerMSteinHJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg2000;232:353–361. )| false
• Search Google Scholar
• Export Citation

HechtmanJFPolydoridesAD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med2012;136:691–697.

HechtmanJFPolydoridesAD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med2012;136:691–697. )| false
• Search Google Scholar
• Export Citation

DreilichMWandersABrattstromD. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus2006;19:224–231.

DreilichMWandersABrattstromD. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus2006;19:224–231. )| false
• Search Google Scholar
• Export Citation

ReicheltUDuesedauPTsourlakisMC. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol2007;20:120–129.

ReicheltUDuesedauPTsourlakisMC. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol2007;20:120–129. )| false
• Search Google Scholar
• Export Citation

SchoppmannSFJeschBFriedrichJ. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol2010;34:1868–1873.

SchoppmannSFJeschBFriedrichJ. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol2010;34:1868–1873. )| false
• Search Google Scholar
• Export Citation

MoelansCBvan DiestPJMilneANOfferhausGJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int2011;2011:674182.

MoelansCBvan DiestPJMilneANOfferhausGJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int2011;2011:674182. )| false
• Search Google Scholar
• Export Citation

GravalosCJimenoA. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol2008;19:1523–1529.

GravalosCJimenoA. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol2008;19:1523–1529. )| false
• Search Google Scholar
• Export Citation

TannerMHollmenMJunttilaTT. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol2005;16:273–278.

TannerMHollmenMJunttilaTT. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol2005;16:273–278. )| false
• Search Google Scholar
• Export Citation

BangYChungHXuJ. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract]. J Clin Oncol2009;27(Suppl 15):Abstract 4556.

BangYChungHXuJ. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract]. J Clin Oncol2009;27(Suppl 15):Abstract 4556. )| false
• Search Google Scholar
• Export Citation

HofmannMStossOShiD. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology2008;52:797–805.

HofmannMStossOShiD. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology2008;52:797–805. )| false
• Search Google Scholar
• Export Citation

RuschoffJDietelMBarettonG. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch2010;457:299–307.

RuschoffJDietelMBarettonG. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch2010;457:299–307. )| false
• Search Google Scholar
• Export Citation

BangYJVan CutsemEFeyereislovaA. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet2010;376:687–697.

BangYJVan CutsemEFeyereislovaA. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet2010;376:687–697. )| false
• Search Google Scholar
• Export Citation

Barros-SilvaJDLeitaoDAfonsoL. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer2009;100:487–493.

Barros-SilvaJDLeitaoDAfonsoL. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer2009;100:487–493. )| false
• Search Google Scholar
• Export Citation

van HagenPHulshofMCvan LanschotJJ. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med2012;366:2074–2084.

van HagenPHulshofMCvan LanschotJJ. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med2012;366:2074–2084. )| false
• Search Google Scholar
• Export Citation

CunninghamDAllumWHStenningSP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med2006;355:11–20.

CunninghamDAllumWHStenningSP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med2006;355:11–20. )| false
• Search Google Scholar
• Export Citation

SteyerbergEWNevilleBAKoppertLB. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol2006;24:4277–4284.

SteyerbergEWNevilleBAKoppertLB. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol2006;24:4277–4284. )| false
• Search Google Scholar
• Export Citation

KrasnaMJReedCEJaklitschMT. Thoracoscopic staging of esophageal cancer: a prospective, multiinstitutional trial. Cancer and Leukemia Group B Thoracic Surgeons. Ann Thorac Surg1995;60:1337–1340.

KrasnaMJReedCEJaklitschMT. Thoracoscopic staging of esophageal cancer: a prospective, multiinstitutional trial. Cancer and Leukemia Group B Thoracic Surgeons. Ann Thorac Surg1995;60:1337–1340. )| false
• Search Google Scholar
• Export Citation

BirkmeyerJDSiewersAEFinlaysonEV. Hospital volume and surgical mortality in the United States. N Engl J Med2002;346:1128–1137.

BirkmeyerJDSiewersAEFinlaysonEV. Hospital volume and surgical mortality in the United States. N Engl J Med2002;346:1128–1137. )| false
• Search Google Scholar
• Export Citation

SwisherSGWynnPPutnamJB. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg2002;123:175–183.

SwisherSGWynnPPutnamJB. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg2002;123:175–183. )| false
• Search Google Scholar
• Export Citation

RuschVW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?Semin Oncol2004;31:444–449.

RuschVW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?Semin Oncol2004;31:444–449. )| false
• Search Google Scholar
• Export Citation

SiewertJRSteinHJFeithM. Adenocarcinoma of the esophagogastric junction. Scand J Surg2006;95:260–269.

SiewertJRSteinHJFeithM. Adenocarcinoma of the esophagogastric junction. Scand J Surg2006;95:260–269. )| false
• Search Google Scholar
• Export Citation

de GraafGWAyantundeAAParsonsSL. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol2007;33:988–992.

de GraafGWAyantundeAAParsonsSL. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol2007;33:988–992. )| false
• Search Google Scholar
• Export Citation

NathJMoorthyKTaniereP. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg2008;95:721–726.

NathJMoorthyKTaniereP. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg2008;95:721–726. )| false
• Search Google Scholar
• Export Citation

GrothSSVirnigBAWhitsonBA. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg2010;139:612–620.

GrothSSVirnigBAWhitsonBA. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg2010;139:612–620. )| false
• Search Google Scholar
• Export Citation

PeyreCGHagenJADeMeesterSR. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg2008;248:979–985.

PeyreCGHagenJADeMeesterSR. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg2008;248:979–985. )| false
• Search Google Scholar
• Export Citation

RizkNPIshwaranHRiceTW. Optimum lymphadenectomy for esophageal cancer. Ann Surg2010;251:46–50.

RizkNPIshwaranHRiceTW. Optimum lymphadenectomy for esophageal cancer. Ann Surg2010;251:46–50. )| false
• Search Google Scholar
• Export Citation

KleinbergLForastiereAA. Chemoradiation in the management of esophageal cancer. J Clin Oncol2007;25:4110–4117.

KleinbergLForastiereAA. Chemoradiation in the management of esophageal cancer. J Clin Oncol2007;25:4110–4117. )| false
• Search Google Scholar
• Export Citation

HerskovicAMartzKal-SarrafM. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med1992;326:1593–1598.

HerskovicAMartzKal-SarrafM. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med1992;326:1593–1598. )| false
• Search Google Scholar
• Export Citation

CooperJSGuoMDHerskovicA. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA1999;281:1623–1627.

CooperJSGuoMDHerskovicA. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA1999;281:1623–1627. )| false
• Search Google Scholar
• Export Citation

MinskyBDPajakTFGinsbergRJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol2002;20:1167–1174.

MinskyBDPajakTFGinsbergRJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol2002;20:1167–1174. )| false
• Search Google Scholar
• Export Citation

LiQQLiuMZHuYH. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus2010;23:253–259.

LiQQLiuMZHuYH. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus2010;23:253–259. )| false
• Search Google Scholar
• Export Citation

RuppertBNWatkinsJMShiraiK. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol2010;33:346–352.

RuppertBNWatkinsJMShiraiK. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol2010;33:346–352. )| false
• Search Google Scholar
• Export Citation

MeertenEVvan RijCTesselaarME. Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: a phase II study [abstract]. J Clin Oncol2010;28(Suppl 15):Abstract e14508.

MeertenEVvan RijCTesselaarME. Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: a phase II study [abstract]. J Clin Oncol2010;28(Suppl 15):Abstract e14508. )| false
• Search Google Scholar
• Export Citation

ConroyTGalaisMPRaoulJL. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol2014;15:305–314.

ConroyTGalaisMPRaoulJL. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol2014;15:305–314. )| false
• Search Google Scholar
• Export Citation

IyerRWilkinsonNDemmyTJavleM. Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol2004;11:665–673.

IyerRWilkinsonNDemmyTJavleM. Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol2004;11:665–673. )| false
• Search Google Scholar
• Export Citation

UrschelJDVasanH. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg2003;185:538–543.

UrschelJDVasanH. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg2003;185:538–543. )| false
• Search Google Scholar
• Export Citation

FioricaFDi BonaDSchepisF. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut2004;53:925–930.

FioricaFDi BonaDSchepisF. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut2004;53:925–930. )| false
• Search Google Scholar
• Export Citation

SjoquistKMBurmeisterBHSmithersBM. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol2011;12:681–692.

SjoquistKMBurmeisterBHSmithersBM. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol2011;12:681–692. )| false
• Search Google Scholar
• Export Citation

SwisherSGHofstetterWKomakiR. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg2010;90:892–898; discussion 898-899.

SwisherSGHofstetterWKomakiR. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg2010;90:892–898; discussion 898-899. )| false
• Search Google Scholar
• Export Citation

CenPCorreaAMLeJH. Adenocarcinoma of the lower esophagus with Barrett’s esophagus or without Barrett’s esophagus: differences in patients’ survival after preoperative chemoradiation. Dis Esophagus2009;22:32–41.

CenPCorreaAMLeJH. Adenocarcinoma of the lower esophagus with Barrett’s esophagus or without Barrett’s esophagus: differences in patients’ survival after preoperative chemoradiation. Dis Esophagus2009;22:32–41. )| false
• Search Google Scholar
• Export Citation

WalshTNNoonanNHollywoodD. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med1996;335:462–467.

WalshTNNoonanNHollywoodD. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med1996;335:462–467. )| false
• Search Google Scholar
• Export Citation

BossetJFGignouxMTribouletJP. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med1997;337:161–167.

BossetJFGignouxMTribouletJP. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med1997;337:161–167. )| false
• Search Google Scholar
• Export Citation

UrbaSGOrringerMBTurrisiA. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol2001;19:305–313.

UrbaSGOrringerMBTurrisiA. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol2001;19:305–313. )| false
• Search Google Scholar
• Export Citation

BainsMSStojadinovicAMinskyB. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg2002;124:270–277.

BainsMSStojadinovicAMinskyB. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg2002;124:270–277. )| false
• Search Google Scholar
• Export Citation

KaklamanosIGWalkerGRFerryK. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol2003;10:754–761.

KaklamanosIGWalkerGRFerryK. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol2003;10:754–761. )| false
• Search Google Scholar
• Export Citation

BurmeisterBHSmithersBMGebskiV. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol2005;6:659–668.

BurmeisterBHSmithersBMGebskiV. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol2005;6:659–668. )| false
• Search Google Scholar
• Export Citation

MarietteCDahanLMornexF. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol2014;32:2416–2422.

MarietteCDahanLMornexF. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol2014;32:2416–2422. )| false
• Search Google Scholar
• Export Citation

OppedijkVvan der GaastAvan LanschotJJ. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol2014;32:385–391.

OppedijkVvan der GaastAvan LanschotJJ. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol2014;32:385–391. )| false
• Search Google Scholar
• Export Citation

TepperJKrasnaMJNiedzwieckiD. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol2008;26:1086–1092.

TepperJKrasnaMJNiedzwieckiD. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol2008;26:1086–1092. )| false
• Search Google Scholar
• Export Citation

BurmeisterBHThomasJMBurmeisterEA. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer2011;47:354–360.

BurmeisterBHThomasJMBurmeisterEA. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer2011;47:354–360. )| false
• Search Google Scholar
• Export Citation

MacdonaldJSSmalleySRBenedettiJ. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med2001;345:725–730.

MacdonaldJSSmalleySRBenedettiJ. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med2001;345:725–730. )| false
• Search Google Scholar
• Export Citation

SmalleySRBenedettiJKHallerDG. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol2012;30:2327–2333.

SmalleySRBenedettiJKHallerDG. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol2012;30:2327–2333. )| false
• Search Google Scholar
• Export Citation

BedardELInculetRIMalthanerRA. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer2001;91:2423–2430.

BedardELInculetRIMalthanerRA. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer2001;91:2423–2430. )| false
• Search Google Scholar
• Export Citation

RiceTWAdelsteinDJChidelMA. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg2003;126:1590–1596.

RiceTWAdelsteinDJChidelMA. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg2003;126:1590–1596. )| false
• Search Google Scholar
• Export Citation

KofoedSCMuhicABaeksgaardL. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg2012;101:26–31.

KofoedSCMuhicABaeksgaardL. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg2012;101:26–31. )| false
• Search Google Scholar
• Export Citation

AdelsteinDJRiceTWRybickiLA. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol2009;4:1264–1269.

AdelsteinDJRiceTWRybickiLA. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol2009;4:1264–1269. )| false
• Search Google Scholar
• Export Citation

FuchsCSTepperJENiedzwieckiD. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101[abstract]. J Clin Oncol2011;29(Suppl 15):Abstract 4003.

FuchsCSTepperJENiedzwieckiD. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101[abstract]. J Clin Oncol2011;29(Suppl 15):Abstract 4003. )| false
• Search Google Scholar
• Export Citation

KelsenDPGinsbergRPajakTF. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med1998;339:1979–1984.

KelsenDPGinsbergRPajakTF. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med1998;339:1979–1984. )| false
• Search Google Scholar
• Export Citation

KelsenDPWinterKAGundersonLL. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol2007;25:3719–3725.

KelsenDPWinterKAGundersonLL. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol2007;25:3719–3725. )| false
• Search Google Scholar
• Export Citation

Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet2002;359:1727–1733.

Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet2002;359:1727–1733. )| false
• Search Google Scholar
• Export Citation

AllumWHStenningSPBancewiczJ. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol2009;27:5062–5067.

AllumWHStenningSPBancewiczJ. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol2009;27:5062–5067. )| false
• Search Google Scholar
• Export Citation

BoonstraJJKokTCWijnhovenBP. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer2011;11:181.

BoonstraJJKokTCWijnhovenBP. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer2011;11:181. )| false
• Search Google Scholar
• Export Citation

ThirionPGMichielsSLe MaitreA. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma [abstract]. J Clin Oncol2007;25(Suppl 18):Abstract 4512.

ThirionPGMichielsSLe MaitreA. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma [abstract]. J Clin Oncol2007;25(Suppl 18):Abstract 4512. )| false
• Search Google Scholar
• Export Citation

YchouMBoigeVPignonJP. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol2011;29:1715–1721.

YchouMBoigeVPignonJP. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol2011;29:1715–1721. )| false
• Search Google Scholar
• Export Citation

LeichmanLBerryBT. Experience with cisplatin in treatment regimens for esophageal cancer. Semin Oncol1991;18:64–72.

LeichmanLBerryBT. Experience with cisplatin in treatment regimens for esophageal cancer. Semin Oncol1991;18:64–72. )| false
• Search Google Scholar
• Export Citation

Muhr-WilkenshoffFHinkelbeinWOhnesorgeI. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis2003;18:330–334.

Muhr-WilkenshoffFHinkelbeinWOhnesorgeI. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis2003;18:330–334. )| false
• Search Google Scholar
• Export Citation

EnzingerPCKulkeMHClarkJW. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci2005;50:2218–2223.

EnzingerPCKulkeMHClarkJW. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci2005;50:2218–2223. )| false
• Search Google Scholar
• Export Citation

BurkartCBokemeyerCKlumpB. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res2007;27:2845–2848.

BurkartCBokemeyerCKlumpB. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res2007;27:2845–2848. )| false
• Search Google Scholar
• Export Citation

MuroKHamaguchiTOhtsuA. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol2004;15:955–959.

MuroKHamaguchiTOhtsuA. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol2004;15:955–959. )| false
• Search Google Scholar
• Export Citation

AlbertssonMJohanssonBFrieslandS. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol2007;24:407–412.

AlbertssonMJohanssonBFrieslandS. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol2007;24:407–412. )| false
• Search Google Scholar
• Export Citation

AjaniJAIlsonDHDaughertyK. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst1994;86:1086–1091.

AjaniJAIlsonDHDaughertyK. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst1994;86:1086–1091. )| false
• Search Google Scholar
• Export Citation

IlsonDHWadleighRGLeichmanLPKelsenDP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol2007;18:898–902.

IlsonDHWadleighRGLeichmanLPKelsenDP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol2007;18:898–902. )| false
• Search Google Scholar
• Export Citation

HarstrickABokemeyerCPreusserP. Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol1992;29:321–322.

HarstrickABokemeyerCPreusserP. Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol1992;29:321–322. )| false
• Search Google Scholar
• Export Citation

IlsonDHAjaniJBhallaK. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol1998;16:1826–1834.

IlsonDHAjaniJBhallaK. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol1998;16:1826–1834. )| false
• Search Google Scholar
• Export Citation

PetraschSWeltAReinacherA. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer1998;78:511–514.

PetraschSWeltAReinacherA. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer1998;78:511–514. )| false
• Search Google Scholar
• Export Citation

IlsonDHForastiereAArquetteM. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J2000;6:316–323.

IlsonDHForastiereAArquetteM. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J2000;6:316–323. )| false
• Search Google Scholar
• Export Citation

AjaniJAFodorMBTjulandinSA. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol2005;23:5660–5667.

AjaniJAFodorMBTjulandinSA. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol2005;23:5660–5667. )| false
• Search Google Scholar
• Export Citation

Van CutsemEMoiseyenkoVMTjulandinS. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol2006;24:4991–4997.

Van CutsemEMoiseyenkoVMTjulandinS. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol2006;24:4991–4997. )| false
• Search Google Scholar
• Export Citation

KimJYDoYRParkKU. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol2010;66:31–36.

KimJYDoYRParkKU. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol2010;66:31–36. )| false
• Search Google Scholar
• Export Citation

Al-BatranSEHartmannJTHofheinzR. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol2008;19:1882–1887.

Al-BatranSEHartmannJTHofheinzR. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol2008;19:1882–1887. )| false
• Search Google Scholar
• Export Citation

ShankaranVMulcahyMFHochsterHS. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: preliminary results of a phase II study [abstract]. Presented at 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 47.

ShankaranVMulcahyMFHochsterHS. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: preliminary results of a phase II study [abstract]. Presented at 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 47. )| false
• Search Google Scholar
• Export Citation

OvermanMJKazmiSMJhambJ. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer2010;116:1446–1453.

OvermanMJKazmiSMJhambJ. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer2010;116:1446–1453. )| false
• Search Google Scholar
• Export Citation

TebbuttNCCumminsMMSourjinaT. Randomised, noncomparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer2010;102:475–481.

TebbuttNCCumminsMMSourjinaT. Randomised, noncomparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer2010;102:475–481. )| false
• Search Google Scholar
• Export Citation

SteinAArnoldDThuss-PatiencePC. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastroesophageal cancer: results of a multicenter phase I/II study. Acta Oncol2014;53:392–398.

SteinAArnoldDThuss-PatiencePC. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastroesophageal cancer: results of a multicenter phase I/II study. Acta Oncol2014;53:392–398. )| false
• Search Google Scholar
• Export Citation

CunninghamDStarlingNRaoS. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med2008;358:36–46.

CunninghamDStarlingNRaoS. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med2008;358:36–46. )| false
• Search Google Scholar
• Export Citation

IlsonDH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park)2004;18:22–25.

IlsonDH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park)2004;18:22–25. )| false
• Search Google Scholar
• Export Citation

DankMZaluskiJBaroneC. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2008;19:1450–1457.

DankMZaluskiJBaroneC. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2008;19:1450–1457. )| false
• Search Google Scholar
• Export Citation

WolffKWeinAReulbachU. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs2009;20:165–173.

WolffKWeinAReulbachU. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs2009;20:165–173. )| false
• Search Google Scholar
• Export Citation

BurtnessBGibsonMEglestonB. Phase II trial of docetaxelirinotecan combination in advanced esophageal cancer. Ann Oncol2009;20:1242–1248.

BurtnessBGibsonMEglestonB. Phase II trial of docetaxelirinotecan combination in advanced esophageal cancer. Ann Oncol2009;20:1242–1248. )| false
• Search Google Scholar
• Export Citation

LustbergMBBekaii-SaabTYoungD. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol2010;5:713–718.

LustbergMBBekaii-SaabTYoungD. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol2010;5:713–718. )| false
• Search Google Scholar
• Export Citation

MoehlerMKanzlerSGeisslerM. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2010;21:71–77.

MoehlerMKanzlerSGeisslerM. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2010;21:71–77. )| false
• Search Google Scholar
• Export Citation

GuimbaudRLouvetCRiesP. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol2014;32:3520–3526.

GuimbaudRLouvetCRiesP. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol2014;32:3520–3526. )| false
• Search Google Scholar
• Export Citation

AssersohnLBrownGCunninghamD. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol2004;15:64–69.

AssersohnLBrownGCunninghamD. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol2004;15:64–69. )| false
• Search Google Scholar
• Export Citation

LearyAAssersohnLCunninghamD. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol2009;64:455–462.

LearyAAssersohnLCunninghamD. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol2009;64:455–462. )| false
• Search Google Scholar
• Export Citation

MauerAMKrautEHKraussSA. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol2005;16:1320–1325.

MauerAMKrautEHKraussSA. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol2005;16:1320–1325. )| false
• Search Google Scholar
• Export Citation

Al-BatranSEHartmannJTProbstS. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol2008;26:1435–1442.

Al-BatranSEHartmannJTProbstS. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol2008;26:1435–1442. )| false
• Search Google Scholar
• Export Citation

El-RayesBFShieldsAZalupskiM. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol2004;15:960–965.

El-RayesBFShieldsAZalupskiM. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol2004;15:960–965. )| false
• Search Google Scholar
• Export Citation

RossPNicolsonMCunninghamD. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol2002;20:1996–2004.

RossPNicolsonMCunninghamD. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol2002;20:1996–2004. )| false
• Search Google Scholar
• Export Citation

UrbaSGChanskyKVanVeldhuizenPJ. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group study. Invest New Drugs2004;22:91–97.

UrbaSGChanskyKVanVeldhuizenPJ. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group study. Invest New Drugs2004;22:91–97. )| false
• Search Google Scholar
• Export Citation

MillarJScullinPMorrisonA. Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer2005;93:1112–1116.

MillarJScullinPMorrisonA. Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer2005;93:1112–1116. )| false
• Search Google Scholar
• Export Citation

HomsMYvan der GaastASiersemaPD. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev2006:CD004063.

HomsMYvan der GaastASiersemaPD. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev2006:CD004063. )| false
• Search Google Scholar
• Export Citation

ShahMASchwartzGK. Treatment of metastatic esophagus and gastric cancer. Semin Oncol2004;31:574–587.

ShahMASchwartzGK. Treatment of metastatic esophagus and gastric cancer. Semin Oncol2004;31:574–587. )| false
• Search Google Scholar
• Export Citation

FuchsCSTomasekJYongCJ. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet2014;383:31–39.

FuchsCSTomasekJYongCJ. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet2014;383:31–39. )| false
• Search Google Scholar
• Export Citation

WilkeHMuroKVan CutsemE. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol2014;15:1224–1235.

WilkeHMuroKVan CutsemE. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol2014;15:1224–1235. )| false
• Search Google Scholar
• Export Citation

van WestreenenHLWesterterpMBossuytPM. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol2004;22:3805–3812.

van WestreenenHLWesterterpMBossuytPM. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol2004;22:3805–3812. )| false
• Search Google Scholar
• Export Citation

RosenbaumSStergarHAntochG. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdominal Imaging2006;31:25–35.

RosenbaumSStergarHAntochG. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdominal Imaging2006;31:25–35. )| false
• Search Google Scholar
• Export Citation

MundenRFMacapinlacHAErasmusJJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging2006;21:137–145.

MundenRFMacapinlacHAErasmusJJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging2006;21:137–145. )| false
• Search Google Scholar
• Export Citation

FlamenPLerutAVan CutsemE. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol2000;18:3202–3210.

FlamenPLerutAVan CutsemE. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol2000;18:3202–3210. )| false
• Search Google Scholar
• Export Citation

FlamenPLerutTHaustermansK. Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imaging2004;48:96–108.

FlamenPLerutTHaustermansK. Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imaging2004;48:96–108. )| false
• Search Google Scholar
• Export Citation

CerfolioRJBryantASOhjaB. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg2005;129:1232–1241.

CerfolioRJBryantASOhjaB. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg2005;129:1232–1241. )| false
• Search Google Scholar
• Export Citation

BlencoweNSWhistanceRNStrongS. Evaluating the role of fluorodeoxyglucose positron emission tomography-computed tomography in multi-disciplinary team recommendations for oesophago-gastric cancer. Br J Cancer2013;109:1445–1450.

BlencoweNSWhistanceRNStrongS. Evaluating the role of fluorodeoxyglucose positron emission tomography-computed tomography in multi-disciplinary team recommendations for oesophago-gastric cancer. Br J Cancer2013;109:1445–1450. )| false
• Search Google Scholar
• Export Citation

DuCZhouYHuangK. Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy. J Gastrointest Surg2011;15:2153–2158.